Attorney's Docket No. <u>034100-003</u>
Application No. **10/500841**Page 3
DT04 Rec'd PCT/PT0 0 7 JUL **2004**

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

- 1. (Original) A peptide or protein having a neovascularization action and containing a basic amino acid cluster region of β 1,6-N-acetylglucosaminyltransferase.
- 2. (Original) The peptide or protein according to Claim 1, wherein the β 1,6-N-acetylglucosaminyltransferase has the following properties:
- (1) Action: N-acetylglucosamine is converted into α -6-D-mannoside using UDP-N-acetylglucosamine as a doner substrate;
- (2) Substrate specificity: If the substrate specificity when GnGn-bi-PA is a receptor is 100%, the substrate specificity when GnGnF-bi-PA is a receptor is about 78%, the substrate specificity when GnGnGn-tri-PA is a receptor is about 125%, and the substrate specificity when GnM-PA is a receptor is about 66%;
 - (3) Optimum pH: 6.2 to 6.3;
- (4) Activity: Mn²⁺ is not necessary for exertion of activity, and activity is not inhibited even in the presence of 20 mM EDTA;
- (5) Molecular weight: About 73,000 (by SDS-PAGE in the absence of a reducing agent) and about 73,000 and about 60,000 (by SDS-PAGE in the presence of a reducing agent);

- (6) Km value: Km values for a receptor GnGn-bi-PA and a donor UDP-GlcNAc are 133 μ M and 3.5 mM, respectively;
 - (7) having the following peptide fragments:
 - (a) Thr-Pro-Trp-Gly-Lys,
 - (b) Asn-lie-Pro-Ser-Tyr-Val,
 - (c) Val-Leu-Asp-Ser-Phe-Gly-Thr-Glu-Pro-Glu-Phe-Asn- His-Ala-Asn-Tyr-Ala,
 - (d) Asp-Leu-Gln-Phe-Leu-Leu, and
 - (e) Asn-Thr-Asp-Phe-Phe-Ile-Gly.
- 3. (Original) The peptide or protein according to Claim 1, wherein the β1,6-N-acetylglucosaminyltransferase has an amino acid sequence containing at least an amino acid sequence as depicted in SEQ ID NO: 6, or an amino acid sequence obtained by modification of one or more amino acids in this amino acid sequence.
- 4. (Original) The peptide or protein according to Claim 1, wherein, in the basic amino acid cluster region, the number of basic amino acids accounts for 30% or more of the total number of amino acids in said region.
- 5. (Original) The peptide or protein according to Claim 1, wherein the basic amino acid cluster region contains at least an amino acid sequence as depicted in SEQ ID NO: 7 or an amino acid sequence obtained by modification of one or more amino acids in this amino acid sequence.

- 6. (Currently Amended) A neovascularization accelerator containing the peptide or protein according to any one of Claims 1 to 5 Claim 1.
- 7. (Original) The neovascularization accelerator according to Claim 6, wherein it is a wound healing agent or a preventing and/or therapeutic agent for arteriosclerosis.
- 8. (Currently Amended) A neovascularization inhibitor screening method, which comprises using the peptide or protein according to any one of Claims 1 to 5.

 Claim 1.
- 9. (Currently Amended) A neovascularization inhibitor screening method, which comprises using a cell capable of secreting the peptide or protein according to any one of Claims 1 to 5 Claim 1 expressed in the cell out of the cell.
- 10. (Currently Amended) The screening method according to Claim 9, wherein the cell is a cell in which the peptide or protein according to any one of Claims 1 to 5 can be highly expressed.
- 11. (Original) A neovascularization inhibitor screening method, which comprises using a protease cutting a mature type β 1,6-N-acetylglucosaminyltransferase anchored on a Golgi body membrane to convert this into a secretory type β 1,6-N-acetylglucosaminyltransferase.

- 12. (Original) The screening method according to Claim 11, wherein the protease is β -secretase.
- 13. (Original) The screening method according to Claim 11, wherein the protease is γ -secretase.
- 14. (Currently Amended) A compound showing a neovascularization inhibiting action in the screening method according to any one of Claims 8 to 13 Claim 8.
- 15. (Currently Amended) A compound showing a neovascularization inhibiting action wherein the compound suppresses expression of the peptide or protein according to any of Claims 1 to 5 Claim 1.
- 16. (Currently Amended) A compound showing a neovascularization inhibiting action wherein the compound suppresses binding of the peptide or protein according to any one of Claims 1 to 5 Claim 1 to heparan sulfate proteoglycan.
- 17. (Currently Amended) A neovascularization inhibitor comprising the compound according to any one of Claims 14 to 16 Claim 14.
- 18. (Original) A neovascularization inhibitor comprising a compound having a γ -secretase inhibiting action.

19. (Original) The neovascularization inhibitor according to Claim 18, wherein the compound having a γ -secretase inhibiting action is a compound represented by the following formula (1):

(wherein, Boc represents a butoxycarbonyl group, OMe represents a methoxy group, Val represents valine, and lle represents isoleucine).

- 20. (Currently Amended) An antibody to the peptide or protein according to any one of Claims 1 to 5 Claim 1.
- 21. (Currently Amended) An assay method for the <u>a</u> peptide or protein according to any one of Claims 1 to 5 having a neovascularization action and containing a basic amino acid cluster region of β1,6-N-acetylglucosaminyltransferase, which comprises said method comprising using the antibody according to Claim 20.
- 22. (Currently Amended) A detection kit for the <u>a</u> peptide or protein according to any one of Claims 1 to 5 having a neovascularization action and containing a basic amino acid cluster region of β1,6-N-acetylglucosaminyltransferase, which comprises said detection kit comprising the antibody according to Claim 20.